The story of 1 day in the life of a #hematopathologist… I’m too exhausted to make a fancy educational thread but here are some amazing 🔬 pics for your viewing pleasure. I diagnosed all cases in one day 🤯 only at @MDAndersonNews Happy almost weekend people 🥂 #hemepath 🧵 1/n
Myeloproliferative neoplasm w/ concurrent BCR::ABL1 and JAK2 V617F ..the megekaryocyte morphology is clue to something beyond CML #mpnsm#PathOutPic 2/
BPDCN with perfect so-called “hand mirror” (red) and “pearl necklace” (black) morphology #BPDCN#PathOutPic 3/
Chronic myeloid leukemia, BCR::ABL1 positive. Note PB left-shifted neutrophils, basophilia, BM micro megs and left-shifted myeloid hyperplasia with increased eosinophils in BM #hemepath#PathOutPic 4/
Post-essential thrombocythemia myelofibrosis in accelerated phase #mpnsm#hemepath#PathOutPic wild platelet clumps and tear drop cells!!! 5/
BCR::ABL1 pos B- lymphoblastic lymphoma with prominent necrosis. Cellular degeneration makes it hard to recognize blasts. Teaching point: Think B-ALL or monoblastic leukemia when you see prominent marrow necrosis #hemepath#pathoutpic FISH pic is BCR::ABL1 7/
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrbocytosis with JAK2 V617F and SF3B1 mut. Note meg morphology, erythroid dysplasia and platelet clumps. #hemepath#pathoutpic#mdssm#mpnsm 9/
And the grand finale.. because it’s not Friday if you don’t see a good acute promyelocytic leukemia with PML::RARA… note Auer rods.. #leusm#hemepath#pathoutpic 10/
And this right here is why I love my job.. the WHO index in its entirety (ok… I’m exaggerating …I know 😅 ) in one day….. #hemepath
• • •
Missing some Tweet in this thread? You can try to
force a refresh
WT1 mutations are present in ~7% of de novo AML, are typically Lof mutation involving exons 7-9 of the gene. They frequently (~15%) co-occur w/ NPM1mut & have detrimental impact in this setting, shown by @AkEisfeld and colleagues in bit.ly/3eWQtXw@LeukemiaJnl
We studies a cohort of de novo NPM1-mut AML. 7% had concurrent WT1 mutations at baseline. 22% (15/67) relapsed; 4 (27%) with newly acquired Lof WT1-mut. Illustrated by @furudateken